The Article by Willem Kuyken and colleagues1 about the effectiveness of mindfulness-based cognitive therapy (MBCT) in prevention of depressive relapses is highly relevant for clinical practice and justifies MBCT as a clinically relevant alternative to maintenance antidepressant medication. We speculate that the design of the study might have biased the results against even stronger measurable effects of MBCT. In the study, general practitioners were recommended to start medication tapering after week 6 of MBCT—so tapering and MBCT treatment obviously overlapped to some extent. Since evidence is accumulating that withdrawal symptoms after discontinuation of selective serotonin reuptake inhibitors (SSRIs) are more detrimental and prolonged than assumed (up to 1 year),2 we suggest that the discontinuation process might have interfered with the therapeutic effects of MBCT. In a systematic review,2 gradual tapering did not eliminate withdrawal reactions. We do not know what the predominant class of medication was in the study by Kuyken and colleagues,1 but it seems likely that SSRIs were involved to a large extent. Thus, we argue that, by consecutively undertaking medication tapering followed by a longer washout period before starting MBCT, even stronger effects of MBCT might be observed. In other studies, responders to cognitive behavioral therapy showed relapse rates of 39% in the 68 weeks after psychotherapy and 68% after discontinuation of medication;3 therefore, the discontinuation syndrome might explain the relatively high relapse rate of 44% in Kuyken and colleagues' study of MBCT.